Form D · Biotechnology
Envisagenics, Inc.
New York, NY · CIK 0001699688
Offering snapshot reported Oct 19, 2021 · SEC filing
- Reported sold
- $19.2M Offering amount: $19.2M
- Investors reported
- 24 Form D · investor count
- Minimum accepted
- $1 Reported outside-investor minimum
- First sale
- Sep 22, 2021 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 19, 2021 | Initial | $19,181,626 | No comparison | 24 | SEC filing |
| Oct 30, 2017 | Amendment | $2,500,000 | No comparison | 6 | SEC filing |
| Mar 3, 2017 | Initial | Yet to sell | No comparison | 0 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-417537
This filing covers the sale and issuance of Series A-4 Preferred Stock, the conversion of certain convertible promissory notes into Series A-1, A-2 and A-3 Preferred Stock and the Common Stock issuable upon conversion of such Preferred Stock.
Source: Form D, filed Oct 19, 2021. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Martin Akerman | Director, Executive |
| Bradley Harris | Executive |
| Maria Luisa Pineda | Director, Executive |
| Alan S. Roemer | Director |
| Grant Verstanding | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
101 6 Th Avenue 3 Rd Floor
New York, NY, 10013
New York, NY, 10013